BBI Solutions expand antibody portfolio

BBI Solutions have launched more than 20 new antibodies in their product portfolio as a result of demands in the market place. This extended portfolio now includes cardiac, cancer, inflammation and fertility markers.

The company had noted rising interest in fertility markers in emerging markets, particularly China, which has recently changed its one child policy. Additionally, as increasing numbers of couples in the developed world desire pregnancies at a later stage in life, fertility tests are required more.

Within cardiac and cancer sectors, the company noted that there is  continuous research being performed for improvements in diagnosis and, as such, has increased focus on the biomarkers for these areas to meet the needs of the market.

“At BBI we continually monitor trends in the market and listen to customer’s needs, so that we can react to market demands and provide products that will help us to improve things like disease diagnosis and in this case help people that may have fertility issues,” said Dr James Steggles, BBI’s commercial manager for antibodies. “Our overarching vision is to create a world where everyone has the opportunity for a better quality of life, and launching products like this is our way of achieving this goal.”

Included in this expanded portfolio are CYFRA 21-1, a tumour marker for non-small cell lung cancer, prostate specific antigen and H-FABP — used as a biomarker for myocardial ischaemia and estradiol.